Gallant is a business that appeared on Season 11 of Shark Tank that specializes in providing stem cell therapy for dogs. It was founded by Aaron Hirschhorn, who had a successful stem cell therapy treatment for chronic back pain.
Inspired by the positive impact of stem cell therapy, Aaron raised $11 million from Silicon Valley businesspeople to start Gallant.
The process of how Gallant works begins with a dog being sterilized by a veterinarian and its reproductive organs being shipped in a special container provided by Gallant.
The organs are then shipped to FDA-approved labs, where the stem cells are separated from the animal and frozen in liquid nitrogen. Gallant’s labs store these stem cells and can be shipped whenever they are needed for treatment.
Gallant offers pet owners the option to collect and store their dogs’ stem cells for a fee. They have two main service plans: a yearly subscription of $95 to collect and store the cells or a lifetime service for $595. Additionally, veterinarians charge around $300 for the harvesting of the cells.
While Gallant faces competition from companies like ForeverTarget150 and Amnio Chor, it has been in business since its inception and continues actively selling its products. The estimated net worth of Gallant is $10 million.
|Product||Canine stem cell therapy|
|Investment Seeking||$500,000 for 2% equity in Gallant|
|Final Deal||$500,000 for 5% equity in Gallant|
|Shark||Lori Greiner and Anne Wojcicki|
|Gallant Episode||Season 11, Episode 8|
|Gallant Business Status||In Business|
|Gallant Website||Visit Website|
|Gallant Net Worth||$5 Million|
What Is Gallant?
Gallant is a company that offers stem cell banking services for pets. They collect and store stem cells from pets, which can be used for potential treatments in the future. The stem cells can help improve the quality of life for pets with osteoarthritis, skin conditions, and chronic dry eye conditions.
Gallant aims to provide pet owners with a way to access the healing power of their pets’ younger stem cells if needed. They offer a service where they collect and store stem cells from pets for potential use in future treatments.
Stem cells are remarkable natural healers that have the potential to treat various conditions and injuries.
As pets age, they may experience the effects of aging, such as joint pain, limited mobility, and irritated skin. Traditional methods of treatment can be expensive and may have harmful side effects. Stem cell therapy offers an alternative approach to address these issues.
Gallant’s stem cell banking service allows pet owners to preserve their pets’ stem cells while they are still young and healthy. By banking these stem cells, pet owners can have a direct line to scientific progress and potential results if their pets require treatment in the future.
The testimonials from pet owners who have used Gallant’s services highlight the relief and peace of mind that stem cell banking brings. Banking the stem cells is handled by Gallant and veterinary professionals, making it easy for pet owners.
The idea of banking stem cells for pets with Gallant could reduce the cost of future treatments for pets and improve their quality of life at the same time.
Who Is The Founder Of Gallant?
The founder of Gallant is Aaron Hirschhorn. Hirschhorn had personal experience with stem cell therapy, having successfully undergone the treatment for his chronic back pain.
When his dog suffered from chronic arthritis, he realized that stem cell therapy could help many animals. Inspired by this realization, he approached his contacts in Silicon Valley and raised an initial capital of $11 million to start Gallant.
Before founding Gallant, Hirschhorn was a successful entrepreneur who founded Dog Vacay, a popular pet-sitting service he later sold to Rover.
The concept behind Gallant originated from Hirschhorn’s belief that the benefits of stem cell therapy, a relatively recent medical development, shouldn’t be confined to humans.
He saw potential in bringing this innovative treatment to pets, especially as many suffer from age-related diseases like arthritis.
The idea is to collect and store the stem cells from pets during routine spaying or neutering procedures, a process that was typically wasted, and use these cells later for regenerative treatments if the pet falls ill.
Before appearing on Shark Tank, Gallant had already made significant strides. They had successfully initiated partnerships with veterinary offices, which receive the kits needed to bank pets’ stem cells and send them for storage.
The company also invested in research and applied for four patents to protect its unique business idea.
Despite these advancements, the company faced challenges, primarily in customer acquisition costs and the high cost of stem cell extraction. These challenges led Gallant to seek additional funding for Shark Tank.
How Was The Shark Tank Pitch Of Gallant?
Aaron Hirschhorn delivered a memorable pitch for Gallant on Shark Tank Season 11. In a visually impactful presentation, he walked into the Shark Tank carrying a basket of puppies.
After handing each shark a puppy, he made a striking claim – that four out of the five puppies would likely suffer from age-related diseases in ten years. To illustrate his point, he called in ‘the Grim Reaper’ to collect all but one of the pups.
Hirschhorn sought an investment of $500,000 for 2% equity in Gallant. He gave a rapid-fire explanation of how Gallant’s stem cell banking service could help pets worldwide, drawing from his experience of alleviating his back pain with stem cell treatments.
He also mentioned his partnerships with veterinary offices, which receive kits to bank pets’ stem cells and send them for storage, and his plans to delve into stem-cell medicine.
Despite Hirschhorn’s dynamic presentation, the Sharks were initially skeptical. They expressed concerns about the company’s financial stability, given that Gallant was losing money on customer acquisition, partly because they paid vets approximately $100 to partake in the stem cell banking process.
Furthermore, the extraction process was costly, causing the company to burn through a lot of funds, which led them to raise $10 million for initial research.
Sharks Mark Cuban and guest Shark Anne Wojcicki seemed on the fence about the proposition, while Kevin O’Leary requested financial numbers.
After hearing Hirschhorn’s pitch, O’Leary made two offers: $500,000 for 2% equity and 2% stock options, or $500,000 for 1% equity and a 10% royalty per kit in perpetuity.
Mark Cuban declined to invest, stating he didn’t believe the company had yet figured out its business model.
However, Shark Lori Greiner saw potential in Gallant. Teaming up with Anne Wojcicki, they offered $500,000 for 8% of the company.
Hirschhorn attempted to negotiate, counter-offering for 4%, but Greiner and Wojcicki countered again with an offer of $500,000 for 5%.
In the end, Hirschhorn accepted this deal, securing an investment from Lori Greiner and Anne Wojcicki.
Did Gallant Get a Deal on Shark Tank?
Yes, Gallant did get a deal on Shark Tank. The company, led by entrepreneur Aaron Hirschhorn, pitched its stem cell banking service for pets on Season 11 of the show.
After delivering a poignant pitch, backed by a personal story and a demonstration involving puppies, Aaron asked for $500,000 in exchange for 2% equity.
The Sharks were initially skeptical, with some expressing concerns about the company’s pricing model and profitability. Kevin O’Leary made two offers; however, Aaron didn’t accept either of them. Mark Cuban also decided not to invest, citing his belief that the company hadn’t quite figured everything out yet.
Eventually, Lori Greiner and guest shark Anne Wojcicki saw potential in the business and decided to collaborate on an offer. They proposed $500,000 for 8% equity in Gallant.
Aaron counter-offered with 4%, which they then countered again with 5%. In the end, Aaron accepted their offer of $500,000 for 5% equity.
Sadly, Aaron Hirschhorn passed away in 2021 in a tragic boating accident. However, his company, Gallant, is still operational and has seen success since its appearance on Shark Tank. It reportedly has an annual revenue of about $5.9 million.
The partnership with Lori and Anne has been beneficial for the business, allowing Aaron’s dream to continue despite his untimely passing.
What Happened To Gallant After Shark Tank?
After Gallant’s appearance on Shark Tank, the company saw a significant increase in its visibility and popularity, which positively impacted its business operations. According to your text, Gallant increased its annual revenue to $2.5 million.
In addition, the company managed to reduce costs associated with banking pets’ stem cells, although they maintained their $95 annual fee. This cost reduction could increase its affordability and appeal to a wider customer base.
However, not all developments were positive. The investment deal made on the show hadn’t closed yet. In fact, despite Shark Anne Wojcicki’s suggestion to reduce the price, founder Aaron Hirschhorn raised the price of the Gallant service from $595 to $890.
The company also introduced a one-time setup plan costing $205. This indicates that the company was still trying to find the optimal pricing strategy to appeal to customers while covering its costs.
Founder Aaron Hirschhorn died tragically in a boating accident in 2021, which marked a significant change in Gallant’s business following their Shark Tank appearance. This was a major blow to the company.
However, despite this unfortunate event, the company remains committed to keeping Hirschhorn’s vision alive. The company continues to operate and produce its services, and as of June 2022, Gallant was still in business, actively selling products worth $5 million annually.
Gallant remains dedicated to improving pet health through innovative stem cell treatments.
Gallant Shark Tank Update
After appearing on Shark Tank, Gallant experienced a boost in subscribers and expanded its services to include other pets like cats and horses. Although the deal with Lori Grenier and Anne Wojcicki did not close, Gallant took the sharks’ advice and increased its prices to generate more revenue.
The company also acquired the vet tech company Cook-Regentec in late 2019, providing additional stem cell technology resources.
Unfortunately, tragedy struck Gallant when Aaron Hirschhorn, the founder and CEO, passed away in March 2021 due to a surfing accident.
Gallant’s president and chief scientific officer, Linda Black, became the new CEO. Despite this loss, Gallant continued operating and fulfilling Hirschhorn’s mission of improving animal health and longevity.
Gallant offers various price plans on its website, allowing customers to access its stem cell treatment services for their pets.
The company provides detailed information about the science behind cell stem therapy, the procedure itself, and clinic locations. Gallant’s services are available in all 50 states.
While Gallant’s social media presence is not consistently active, it has been featured in publications such as Forbes, the Daily Mail, and TechCrunch. The company’s estimated annual revenue is $5 million, with a net worth of $7 million as of 2022.
Moving forward, Gallant aims to continue honoring Hirschhorn’s vision and mission of providing animals with a healthy and happy life.
Additionally, Hirschhorn envisioned that Gallant’s services would benefit pets and raise awareness among owners about the potential of stem cell therapy for human health.
Gallant strives to become a leading force in the pet health industry and inspire people to explore the possibilities of stem cell therapy further.
Is Gallant Still In Business?
Our research shows that Gallant is still in business. However, it is mentioned that the founder of Gallant, Aaron Hirschhorn, passed away in 2021 due to a boating accident.
Despite his passing, partnering with Lori Greiner and Anne Wojcicki has allowed his dream to continue. Gallant has also increased its yearly revenue to about $5.9 million and has a great board of people and veterinarians supporting its success.
What Is the Net Worth Of Gallant?
According to our research, the net worth of Gallant is estimated to be $45 million. The valuation of Gallant was $10 million after securing an investment from Lori Greiner and Anne Wojcicki on Shark Tank.
Also, read about other businesses that appeared on Season 11 of Shark Tank:
- Critter Pricker Shark Tank Update | Critter Pricker Net Worth
- Rescue Ready Shark Tank Update | Rescue Ready Net Worth
- Yellow Leaf Hammocks Shark Tank Net Worth
- Proven Skincare Shark Tank Update | Proven Skincare Net Worth
- Atlas Monroe Shark Tank Update | Atlas Monroe Net Worth
- Boost Oxygen Shark Tank Update | Boost Oxygen Net Worth